Free Newsletter
No monitoring for Vioxx-takers, court says
Slowly but surely Merck is working its way off the Vioxx hook. First, the successful fight-em-one-by-one strategy, then the big settlement, then a few key overturned verdicts--and now, the New Jersey Supreme Court has ruled that the drugmaker doesn't have to monitor Vioxx patients for future health problems. The 5-1 decision nullifies a class action lawsuit, filed by Vioxx users who don't have symptoms but wanted to be tested for any hidden problems.
The ruling states that patients can't pursue claims for medical monitoring unless they show "harm." Because these plaintiffs had no injuries to report, no harm done--in a legal sense, anyway.
- check out Merck's release
- read the Los Angeles Times story
- see the article in the Star-Ledger
Related Articles:
Vioxx plaintiffs sign on, deal proceeds
Vioxx deal faces pitfalls
Vioxx settlement spawns mega-chatter
Merck takes tough stance on Vioxx
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: